Clinical Trial Update: Arsenic Trioxide, Ascorbic Acid, Dexamethasone, and Thalidomide in Treating Patients With Multiple Myeloma [Phase 2]

View source ↗

Summary

A Phase 2 trial evaluating arsenic trioxide, ascorbic acid, dexamethasone, and thalidomide in multiple myeloma has been withdrawn. The study was sponsored by Th…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Multiple Myeloma
• Plasma Cell Neoplasms

Drugs mentioned

• Arsenic Trioxide (arsenic trioxide)
• Ascorbic acid (Vitamin C)
• DEXAMETHASONE (Dexamethasone)
• Thalidomide (thalidomide)

Snippet

Sponsor: The Cleveland Clinic | Conditions: Stage I Multiple Myeloma, Stage II Multiple Myeloma | Phase 2 | Status: WITHDRAWN